A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1464-410x|116|4|546-555

ISSN： 1464-4096

Source： BJU INTERNATIONAL, Vol.116, Iss.4, 2015-10, pp. : 546-555

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications

By  

CANCER, Vol. 121, Iss. 21, 2015-11 ,pp. : 3853-3861

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: A retrospective study

By  

THE PROSTATE, Vol. 78, Iss. 4, 2018-03 ,pp. : 278-278

John Wiley & Sons Inc

Access to resources Recommend Favorite